Praziquantel

EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Retrieved on: 
Monday, December 18, 2023
World Health Organization, Global health, Schistosomiasis, European Medicines Agency, Consortium, WHO, Disease, Tablet, Clinical trial, EMA, Schistosoma haematobium, European, Vaccine, CHMP, Parasitism, Health, Committee, Child, Blood, Praziquantel, Neglected tropical diseases, Infection, Universal Corporation, Water, Partnership, Swimming, Skin, Schistosoma mansoni, Taste, Pharmaceutical industry, Nursing, Merck

TOKYO, Dec. 18, 2023 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund has supported the Pediatric Praziquantel Consortium's development of arpraziquantel since 2013 through a total investment of approximately 1.85 billion Japanese yen. On December 15, the Consortium announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion for arpraziquantel to treat schistosomiasis in preschool-aged children. Arpraziquantel is the first investigational drug to receive positive scientific opinion amongst the projects funded by the GHIT Fund. Present in 78 countries and endemic in 51, schistosomiasis affects more than 240 million people, about 50 million of whom are preschool-aged children. Leveraging Japanese innovation and leadership in the global fight against neglected tropical diseases (NTDs), GHIT Fund invests in global health R&D and facilitates transformational cross-border public-private partnerships.

Key Points: 
  • On December 15, the Consortium announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion for arpraziquantel to treat schistosomiasis in preschool-aged children.
  • Present in 78 countries and endemic in 51, schistosomiasis affects more than 240 million people, about 50 million of whom are preschool-aged children.
  • Extending the range of options for the treatment of schistosomiasis, arpraziquantel is tailored for preschool-aged children against Schistosoma mansoni and Schistosoma haematobium.
  • Its mission is to develop, register, and provide access to a suitable pediatric drug for treating schistosomiasis in children 3 months to 6 years of age.

Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS (afoxolaner, moxidectin and pyrantel chewable tablets): A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites

Retrieved on: 
Thursday, July 20, 2023
Seizure, Afoxolaner, Human, Companion Animal Parasite Council, Tremor, Parasitism, Prevalence, Diarrhea, Breeding, Veterinarian, Dog, Farmer, Coccidioides immitis, Season, Health, Ataxia, DSM-IV codes, Livestock, Animal Health, Moxidectin, Tick, Tablet, Boehringer Ingelheim, Vomiting, CAPC, Animal, Patient, Freezing, Lethargy, Eprinomectin, Pet, Itch, FDA, Ivermectin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Praziquantel, Internal, DVM, Veterinary medicine, Food, Boehringer Ingelheim Animal Health, Cat, Bottled water, Medical device, Vaccine, Pharmaceutical industry, Dietary supplement

By combining internal and external parasite protection in a tasty, beef-flavored soft chew, NexGard® PLUS helps make monthly compliance easy and enjoyable for pets and pet owners.

Key Points: 
  • By combining internal and external parasite protection in a tasty, beef-flavored soft chew, NexGard® PLUS helps make monthly compliance easy and enjoyable for pets and pet owners.
  • Each NexGard® PLUS chew has the same proven afoxolaner dose prescribed to millions of dogs in NexGard® (afoxolaner),6 and an optimized dose of moxidectin that is proven safe and effective.
  • To further enable compliance, veterinarians can prescribe 3-dose and 6-dose presentations to best support the needs of their canine patients.
  • NexGard® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) are for use in dogs only.

Veterinary API Market worth $7.1 billion | MarketsandMarkets

Retrieved on: 
Wednesday, June 21, 2023
Analgesic, Administration, Veterinarian, Veterinary medicine, API, Praziquantel, Zero-turn mower, Livestock, NGL, Research, Animal, Tablet, Research and development, Route, Capsule, Anthelmintic, Investment, Economic development, Oral, Growth, Health, Recession, Safety, Fine chemical, Vaccine

The Veterinary API Market is segmented based on animal type into two categories: companion animals and livestock animals.

Key Points: 
  • The Veterinary API Market is segmented based on animal type into two categories: companion animals and livestock animals.
  • In 2022, companion animals dominated the Veterinary API Market, holding the largest market share.
  • Collaboration and Partnerships: The Veterinary API market encourages collaboration and partnerships among pharmaceutical companies, research institutions, and veterinary professionals.
  • By fostering collaboration, the Veterinary API market strengthens the collective expertise and resources dedicated to improving veterinary healthcare.

Veterinary API Market worth $7.1 billion | MarketsandMarkets

Retrieved on: 
Wednesday, June 21, 2023
Analgesic, Administration, Veterinarian, Veterinary medicine, API, Praziquantel, Zero-turn mower, Livestock, NGL, Research, Animal, Tablet, Research and development, Route, Capsule, Anthelmintic, Investment, Economic development, Oral, Growth, Health, Recession, Safety, Fine chemical, Vaccine

The Veterinary API Market is segmented based on animal type into two categories: companion animals and livestock animals.

Key Points: 
  • The Veterinary API Market is segmented based on animal type into two categories: companion animals and livestock animals.
  • In 2022, companion animals dominated the Veterinary API Market, holding the largest market share.
  • Collaboration and Partnerships: The Veterinary API market encourages collaboration and partnerships among pharmaceutical companies, research institutions, and veterinary professionals.
  • By fostering collaboration, the Veterinary API market strengthens the collective expertise and resources dedicated to improving veterinary healthcare.

Boehringer Ingelheim Introduces NexGard® COMBO (esafoxolaner, eprinomectin, and praziquantel topical solution): The First-and-Only Feline Broad-Spectrum Parasite Protection that Treats Tapeworms

Retrieved on: 
Monday, April 24, 2023
Seizure, Afoxolaner, Human, Tick, Tremor, Argyreia nervosa, Diarrhea, Hypersalivation, Breeding, Veterinarian, Farmer, Health, Ataxia, Parasitism, DSM-IV codes, Livestock, Coccidioides immitis, Animal Health, History, Boehringer Ingelheim, Vomiting, Animal, Patient, Lethargy, Dog, Itch, Eprinomectin, Pet, Parasitic disease, COMBO, FDA, Praziquantel, Veterinary medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, DVM, Food, Boehringer Ingelheim Animal Health, Cat, Pharmaceutical industry, Fine chemical, Medical device, Dipylidium caninum

It is the first-and-only feline broad-spectrum protection against fleas, ticks, roundworms, hookworms, heartworm disease and tapeworms.

Key Points: 
  • It is the first-and-only feline broad-spectrum protection against fleas, ticks, roundworms, hookworms, heartworm disease and tapeworms.
  • NexGard® COMBO is a one-and-done, monthly topical solution, specially formulated for feline patients, that helps make compliance easy.
  • To further enable compliance, veterinarians can prescribe 3-dose and 6-dose presentations to best support the needs of their feline patients.
  • Together, NexGard® COMBO brings monthly one-and-done, broad-spectrum protection against internal and external parasites — that includes tapeworms — to cats for the first time.

The European Medicines Agency (EMA) Validated Regulatory Application for Arpraziquantel, a Potential Treatment for Schistosomiasis in Preschool-Aged Children

Retrieved on: 
Monday, January 23, 2023
UNDP, Snail, Human, European Medicines Agency, Health, Tropics, Partnership, Institute for Colored Youth, SCI, PPP, Kenya Medical Research Institute, Disease, Government of Japan, Swiss Tropical and Public Health Institute, Schistosoma mansoni, Death, Parasitism, Schistosoma haematobium, SCI Foundation, Volunteering, Water, Ministry, Vaccine, Anemia, Consortium, Research, Malaria, Global Health Innovative Technology Fund, Taste, EMA, Learning, Drinking water, Skin, Tuberculosis, Praziquantel, Tropical disease, Bill & Melinda Gates Foundation, Bill, United Nations Development Programme, Child, Tropical climate, United Nations, Pharmaceutical industry, Birth control, Merck, Wellcome, Schistosomiasis

Arpraziquantel, developed by the Pediatric Praziquantel Consortium, is a potential new treatment option tailored to improve child health by filling the treatment gap of an estimated 50 million preschool-aged children with schistosomiasis.

Key Points: 
  • Arpraziquantel, developed by the Pediatric Praziquantel Consortium, is a potential new treatment option tailored to improve child health by filling the treatment gap of an estimated 50 million preschool-aged children with schistosomiasis.
  • On behalf of the Pediatric Praziquantel Consortium, Merck submitted the regulatory application for arpraziquantel to the European Medicines Agency (EMA), which validated this application and started the scientific review process in December 2022.
  • Arpraziquantel represents the first investigational drug that has reached the regulatory phase amongst the portfolio of projects supported by GHIT Fund.
  • The drug praziquantel – the current standard treatment developed in the 1970s – is safe, effective and available for school-aged children and adults.

Flea, Tick, And Heartworm Products Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Thursday, December 22, 2022
EntirelyPets, US, COVID-19, Flea, Animal, Hair, Parasitism, Loneliness, Research, Praziquantel, Dog, Unicharm, Ivermectin, Pyrantel, Exocrine gland, Tick, Skin, Cat, Forecasting, Family, Heart, Growth, Acquisition, Organization, Anthelmintic, Cestoda, Merck, Dermatitis, Eli Lilly and Company, Perrigo, Human, Bayer, Geography, Pet, Dietary supplement, Virbac

The lea, tick, and heartworm products market is expected to reach $3.68 billion in 2026 at a CAGR of 9.4%.

Key Points: 
  • The lea, tick, and heartworm products market is expected to reach $3.68 billion in 2026 at a CAGR of 9.4%.
  • North America was the largest region in the flea, tick, and heartworm products market in 2021.Europe was the second largest region in the flea, tick, and heartworm products market.
  • Product innovation is a key trend gaining popularity in the flea, tick, and heartworm products market.Major companies in the flea, tick, and heartworm products market are advancing in their new technologies and research and developments in the flea, tick, and heartworm products market.
  • The flea, tick, and heartworm products market research report is one of a series of new reports that provides flea, tick, and heartworm products market statistics, including flea, tick, and heartworm products industry global market size, regional shares, competitors with flea, tick, and heartworm products market share, detailed flea, tick, and heartworm products market segments, market trends, and opportunities, and any further data you may need to thrive in the flea, tick, and heartworm products industry.

Felpreva®, Vetoquinol’s New Three-Monthly Feline Parasiticide, Receives Marketing Authorisation from the European Commission

Retrieved on: 
Monday, November 22, 2021
Biotechnology, Consumer, Health, Pets, Veterinary, Royal commission, Parasitism, Euronext Paris, International Range Officers Association, MITES, CVMP, Ricinus, EU6, Committee for Medicinal Products for Veterinary Use, Committee, Medicine, Otodectes, Alternative veterinary medicine, Livestock, Veterinarian, Praziquantel, Research, MacNamara, Risk, Cat, PEA, European Commission, Parasites & Vectors, Ixodes holocyclus, Veterinary medicine, Ctenocephalides, FAD, Animal, PETS, Tick, Cattle, Pet

Matthieu Frechin, Vetoquinol CEO, commented: Marketing authorisation is a pivotal achievement for both Vetoquinol and Felpreva.

Key Points: 
  • Matthieu Frechin, Vetoquinol CEO, commented: Marketing authorisation is a pivotal achievement for both Vetoquinol and Felpreva.
  • It is a breakthrough treatment with convenience and simplicity of use combined with long-lasting efficacy.
  • We believe that Felpreva will be a real game changer for this area of veterinary medicine, demonstrating our commitment to the parasiticide market.
  • Felpreva is part of the endectocide class of veterinary parasiticides that covers both internal (endo) and external (ecto) parasites.

Veterinary Parasiticide Felpreva® (tigolaner / emodepside / praziquantel) Receives Positive Opinion From European Committee for Medicinal Products for Veterinary Use (CVMP)

Retrieved on: 
Tuesday, September 14, 2021
Health, Consumer, Pets, Research, Science, Veterinary, Health, Consumer, Pets, Research, Science, Veterinary

Vetoquinol (Paris: VETO) today announced that the European Medicines Agencys Committee for Medicinal Products for Veterinary Use (CVMP) has adopted a positive opinion recommending the granting of a marketing authorization of Felpreva spot-on solution (tigolaner, emodepside, praziquantel).

Key Points: 
  • Vetoquinol (Paris: VETO) today announced that the European Medicines Agencys Committee for Medicinal Products for Veterinary Use (CVMP) has adopted a positive opinion recommending the granting of a marketing authorization of Felpreva spot-on solution (tigolaner, emodepside, praziquantel).
  • Following an anticipated positive decision from the European Medicines Agency on Vetoquinols application for marketing authorization of Felpreva, the veterinary medicinal product is expected to be available to veterinarians across Europe in 2022.
  • For any specific enquiries about Felpreva, please email: [email protected]
    1 EMA Summary of Positive Opinion Felpreva.
  • With a range of successful and trusted veterinary parasiticide products, Vetoquinol has rapidly become an important player in the global companion animal veterinary parasiticides market.

GHIT Fund Announces New Investments: A Total of 2.86 Billion Yen in Drug for Schistosomiasis, Dengue, Malaria and Tuberculosis, Vaccines for Leishmaniasis and Malaria, and Diagnostics for Tuberculosis

Retrieved on: 
Thursday, March 28, 2019
Infectious diseases, Medical specialties, Medicine, RTT, Neglected diseases, Simcyp, Helminthiases, Waterborne diseases, Kenya Medical Research Institute, Praziquantel, Schistosomiasis

Its mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in this age group.

Key Points: 
  • Its mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in this age group.
  • At the end of 2017 Simcyp completed all its tasks around PK modeling and left the Consortium.
  • In Jan 2018 Universit Flix Houphout Boigny (UFHB) and Kenya Medical Research Institute (KEMRI) joined the consortium as new partners.
  • The core project team is supported by various subteams focusing on specific technical and operational aspects to implement the consortium's program.